261 related articles for article (PubMed ID: 8413278)
1. The tumor suppressor p53 and the oncoprotein simian virus 40 T antigen bind to overlapping domains on the MDM2 protein.
Brown DR; Deb S; Muñoz RM; Subler MA; Deb SP
Mol Cell Biol; 1993 Nov; 13(11):6849-57. PubMed ID: 8413278
[TBL] [Abstract][Full Text] [Related]
2. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene.
Chen J; Lin J; Levine AJ
Mol Med; 1995 Jan; 1(2):142-52. PubMed ID: 8529093
[TBL] [Abstract][Full Text] [Related]
3. N-terminal 130 amino acids of MDM2 are sufficient to inhibit p53-mediated transcriptional activation.
Leng P; Brown DR; Shivakumar CV; Deb S; Deb SP
Oncogene; 1995 Apr; 10(7):1275-82. PubMed ID: 7731677
[TBL] [Abstract][Full Text] [Related]
4. Physical and functional interactions between PML and MDM2.
Wei X; Yu ZK; Ramalingam A; Grossman SR; Yu JH; Bloch DB; Maki CG
J Biol Chem; 2003 Aug; 278(31):29288-97. PubMed ID: 12759344
[TBL] [Abstract][Full Text] [Related]
5. Physical and functional interaction between wild-type p53 and mdm2 proteins.
Haines DS; Landers JE; Engle LJ; George DL
Mol Cell Biol; 1994 Feb; 14(2):1171-8. PubMed ID: 8289798
[TBL] [Abstract][Full Text] [Related]
6. A genetic approach to mapping the p53 binding site in the MDM2 protein.
Freedman DA; Epstein CB; Roth JC; Levine AJ
Mol Med; 1997 Apr; 3(4):248-59. PubMed ID: 9131587
[TBL] [Abstract][Full Text] [Related]
7. MdmX protects p53 from Mdm2-mediated degradation.
Jackson MW; Berberich SJ
Mol Cell Biol; 2000 Feb; 20(3):1001-7. PubMed ID: 10629057
[TBL] [Abstract][Full Text] [Related]
8. The human oncoprotein MDM2 uses distinct strategies to inhibit transcriptional activation mediated by the wild-type p53 and its tumor-derived mutants.
Brown DR; Deb D; Frum R; Hickes L; Munoz R; Deb S; Deb SP
Int J Oncol; 2001 Mar; 18(3):449-59. PubMed ID: 11179471
[TBL] [Abstract][Full Text] [Related]
9. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.
Lin J; Chen J; Elenbaas B; Levine AJ
Genes Dev; 1994 May; 8(10):1235-46. PubMed ID: 7926727
[TBL] [Abstract][Full Text] [Related]
10. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.
Kussie PH; Gorina S; Marechal V; Elenbaas B; Moreau J; Levine AJ; Pavletich NP
Science; 1996 Nov; 274(5289):948-53. PubMed ID: 8875929
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
Ghosh M; Huang K; Berberich SJ
Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
[TBL] [Abstract][Full Text] [Related]
12. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53.
Oliner JD; Pietenpol JA; Thiagalingam S; Gyuris J; Kinzler KW; Vogelstein B
Nature; 1993 Apr; 362(6423):857-60. PubMed ID: 8479525
[TBL] [Abstract][Full Text] [Related]
13. Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination.
Nakamura S; Roth JA; Mukhopadhyay T
Mol Cell Biol; 2000 Dec; 20(24):9391-8. PubMed ID: 11094089
[TBL] [Abstract][Full Text] [Related]
14. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.
Midgley CA; Desterro JM; Saville MK; Howard S; Sparks A; Hay RT; Lane DP
Oncogene; 2000 May; 19(19):2312-23. PubMed ID: 10822382
[TBL] [Abstract][Full Text] [Related]
15. Identification of the p53 protein domain involved in formation of the simian virus 40 large T-antigen-p53 protein complex.
Tan TH; Wallis J; Levine AJ
J Virol; 1986 Sep; 59(3):574-83. PubMed ID: 3016321
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional regulation of the mdm2 oncogene by p53 requires TRRAP acetyltransferase complexes.
Ard PG; Chatterjee C; Kunjibettu S; Adside LR; Gralinski LE; McMahon SB
Mol Cell Biol; 2002 Aug; 22(16):5650-61. PubMed ID: 12138177
[TBL] [Abstract][Full Text] [Related]
17. p53, p21(WAF1/CIP1), and MDM2 involvement in proliferation and apoptosis in an in vitro model of conditionally immortalized human vascular smooth muscle cells.
Hsieh JK; Kletsas D; Clunn G; Hughes AD; Schachter M; Demoliou-Mason C
Arterioscler Thromb Vasc Biol; 2000 Mar; 20(3):636-44. PubMed ID: 10712385
[TBL] [Abstract][Full Text] [Related]
18. p53 and SV40 T antigen bind to the same region overlapping the conserved domain of the TATA-binding protein.
Martin DW; Subler MA; Muñoz RM; Brown DR; Deb SP; Deb S
Biochem Biophys Res Commun; 1993 Aug; 195(1):428-34. PubMed ID: 8395834
[TBL] [Abstract][Full Text] [Related]
19. The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo.
Shimizu H; Burch LR; Smith AJ; Dornan D; Wallace M; Ball KL; Hupp TR
J Biol Chem; 2002 Aug; 277(32):28446-58. PubMed ID: 11925449
[TBL] [Abstract][Full Text] [Related]
20. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein.
Mietz JA; Unger T; Huibregtse JM; Howley PM
EMBO J; 1992 Dec; 11(13):5013-20. PubMed ID: 1464323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
